ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by Globeflex Capital L P

Globeflex Capital L P increased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 80.9% in the fourth quarter, Holdings Channel reports. The firm owned 55,361 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,757 shares during the quarter. Globeflex Capital L P’s holdings in ANI Pharmaceuticals were worth $4,370,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Illinois Municipal Retirement Fund grew its stake in ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after purchasing an additional 145 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after purchasing an additional 198 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after purchasing an additional 200 shares in the last quarter. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in ANI Pharmaceuticals by 30.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after purchasing an additional 253 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $79.20 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The business has a 50 day moving average of $78.92 and a two-hundred day moving average of $79.38. ANI Pharmaceuticals, Inc. has a 52 week low of $59.61 and a 52 week high of $99.50. The company has a market cap of $1.80 billion, a P/E ratio of 20.05 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.96 EPS for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research reports. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Thomas Andrew Rowland sold 4,772 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the completion of the transaction, the senior vice president directly owned 38,730 shares in the company, valued at approximately $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the transaction, the director owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This represents a 20.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 81,638 shares of company stock valued at $6,348,562. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.